{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:33:29Z","timestamp":1792179209100,"version":"4.4.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The clinical efficacy of current therapies for Hepatocellular carcinoma (HCC) are unsatisfactory. In recent years, chimeric antigen receptor (CAR) T-cell therapies have been developed for solid tumors including advanced HCC (aHCC), but limited progress has been made. Glypican-3 is a promising immunotherapeutic target for HCC since it is specifically highly expressed in HCC. A previous study indicated that GPC3-targeted CAR T-(CAR-GPC3) cells were well-tolerated and had prolonged survival for HCC patients and that Sorafenib could increase the antitumor activities of CAR-GPC3 T-cells against HCC in mouse models. Here, we report a patient with aHCC who achieved a complete response (CR) and a long survival period after the combination therapy of CAR-GPC3 T-cell plus sorafenib.<\/jats:p><jats:p>A 60-year-old Asian male diagnosed with hepatitis B virus (HBV) related HCC developed liver recurrence and lung metastasis after liver tumor resection and trans-arterial chemoembolization therapy. The patient also previously received microwave ablation therapy for lung metastasis. After the enrollment, the patient underwent leukapheresis for CAR-GPC3 T-cells manufacturing. Seven days after leukapheresis, the patient started to receive 400 mg of Sorafenib twice daily. The patient received 4 cycles of CAR-GPC3 T cells (CT011) treatment and each cycle was divided into two infusions. Prior to each cycle of CT011 treatment, lymphodepletion was performed. The lymphodepletion regimen was cyclophosphamide 500 mg\/m<jats:sup>2<\/jats:sup>\/day for 2 to 3 days, and fludarabine 20-25 mg\/m<jats:sup>2<\/jats:sup>\/day for 3 to 4 days. A total of 4\u00d710<jats:sup>9<\/jats:sup> CAR-GPC3 T cells were infused. The CT011 plus Sorafenib combination therapy was well tolerated. All the \u2265 grade 3 AEs were hematological toxicities which were deemed an expected event caused by the preconditioning regimen. This patient obtained partial responses from the 3<jats:sup>rd<\/jats:sup> month and achieved CR in the 12<jats:sup>th<\/jats:sup> month after the first cycle of CT011 infusion according to the RECIST1.1 assessment. The tumor had no progression for more than 36 months and maintained the CR status for more than 24 months after the first infusion.<\/jats:p>","DOI":"10.3389\/fimmu.2022.963031","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T06:47:50Z","timestamp":1660718870000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Long term complete response of advanced hepatocellular carcinoma to glypican-3 specific chimeric antigen receptor T-Cells plus sorafenib, a case report"],"prefix":"10.3389","volume":"13","author":[{"given":"Hongwei","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongyun","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songfu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjie","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongru","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuepeng","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfeng","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huamao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zonghai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keqing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: Cancer J Clin"},{"key":"B2","article-title":"Hepatobiliary cancers, version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Benson","year":"2021","journal-title":"Journal of the National Comprehensive Cancer Network : JNCCN"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"New Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0986","article-title":"Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy","volume":"17","author":"Rizzo","year":"2021","journal-title":"Future Oncol (London England)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1186\/s12885-021-08858-6","article-title":"Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study","volume":"21","author":"Chen","year":"2021","journal-title":"BMC Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1440169","article-title":"CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial","volume":"7","author":"Wang","year":"2018","journal-title":"Oncoimmunology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3259","article-title":"Chimeric antigen receptor-Glypican-3 T-cell therapy for advanced hepatocellular carcinoma: Results of phase I trials","volume":"26","author":"Shi","year":"2020","journal-title":"Clin Cancer Res an Off J Am Assoc Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.17905","article-title":"Treatment of hepatocellular carcinoma with a GPC3-targeted bispecific T cell engager","volume":"8","author":"Bi","year":"2017","journal-title":"Oncotarget"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1170","article-title":"Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma","volume":"20","author":"Gao","year":"2014","journal-title":"Clin Cancer Res an Off J Am Assoc Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"New Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27665","article-title":"CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice","volume":"61","author":"Chen","year":"2015","journal-title":"Hepatol (Baltimore Md)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1159\/000489021","article-title":"Increased expression of programmed death-ligand 1 in infiltrating immune cells in hepatocellular carcinoma tissues after sorafenib treatment","volume":"8","author":"Lu","year":"2019","journal-title":"Liver Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.04.020","article-title":"Combined antitumor effects of sorafenib and GPC3-CAR T cells in mouse models of hepatocellular carcinoma","volume":"27","author":"Wu","year":"2019","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.738456","article-title":"Genetic modification of cytokine signaling to enhance efficacy of CAR T cell therapy in solid tumors","volume":"12","author":"Ghahri-Saremi","year":"2021","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-021-00655-2","article-title":"Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment","volume":"18","author":"Liu","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.09.006","article-title":"Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors","volume":"36","author":"Grosser","year":"2019","journal-title":"Cancer Cell"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0293","article-title":"Glypican-3-Specific CAR T cells coexpressing IL15 and IL21 have superior expansion and antitumor activity against hepatocellular carcinoma","volume":"8","author":"Batra","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/S0006-291X(03)00908-2","article-title":"Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker","volume":"306","author":"Nakatsura","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-013-0793-2","article-title":"Positive glypican-3 expression in early hepatocellular carcinoma predicts recurrence after hepatectomy","volume":"49","author":"Chen","year":"2014","journal-title":"J Gastroenterol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2009.01206.x","article-title":"Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma","volume":"100","author":"Shirakawa","year":"2009","journal-title":"Cancer Sci"},{"key":"B25","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3389\/fonc.2019.00108","article-title":"Immunotherapeutic targeting of GPC3 in pediatric solid embryonal tumors","volume":"9","author":"Ortiz","year":"2019","journal-title":"Front Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00248","article-title":"Next-generation cancer immunotherapy targeting glypican-3","volume":"9","author":"Shimizu","year":"2019","journal-title":"Front Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00690","article-title":"Anti-GPC3-CAR T cells suppress the growth of tumor cells in patient-derived xenografts of hepatocellular carcinoma","volume":"7","author":"Jiang","year":"2016","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14771","article-title":"Co-Expression of IL-7 and PH20 promote anti-GPC3 CAR-T tumour suppressor activity in vivo and in vitro","volume":"41","author":"Xiong","year":"2021","journal-title":"Liver Int Off J Int Assoc Stud Liver"},{"key":"B29","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13045-021-01128-9","article-title":"IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin","volume":"14","author":"Pang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1053\/j.gastro.2020.02.011","article-title":"Persistent polyfunctional chimeric antigen receptor T cells that target glypican 3 eliminate orthotopic hepatocellular carcinomas in mice","volume":"158","author":"Li","year":"2020","journal-title":"Gastroenterology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1200\/JCO.2017.35.15_suppl.3049","article-title":"A phase I study of anti-GPC3 chimeric antigen receptor modified T cells (GPC3 CAR-T) in Chinese patients with refractory or relapsed GPC3+ hepatocellular carcinoma (r\/r GPC3+ HCC)","author":"Zhai","year":"2017","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12935-021-02435-4","article-title":"Modulation of the tumour microenvironment in hepatocellular carcinoma by tyrosine kinase inhibitors: from modulation to combination therapy targeting the microenvironment","volume":"22","author":"Chen","year":"2022","journal-title":"Cancer Cell Int"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2130","article-title":"Discovery and development of sorafenib: a multikinase inhibitor for treating cancer","volume":"5","author":"Wilhelm","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-1377","article-title":"Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5","volume":"66","author":"Liu","year":"2006","journal-title":"Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2010.07.002","article-title":"The multikinase inhibitor sorafenib reverses the suppression of IL-12 and enhancement of IL-10 by PGE\u2082 in murine macrophages","volume":"10","author":"Edwards","year":"2010","journal-title":"Int Immunopharmacol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26328","article-title":"Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells","volume":"57","author":"Sprinzl","year":"2013","journal-title":"Hepatol (Baltimore Md)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00070","article-title":"Control of the immune response by pro-angiogenic factors","volume":"4","author":"Voron","year":"2014","journal-title":"Front Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000496277","article-title":"Combination cancer immunotherapy with molecular targeted Agents\/Anti-CTLA-4 antibody for hepatocellular carcinoma","volume":"8","author":"Kudo","year":"2019","journal-title":"Liver Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-019-06189-6","article-title":"Radiofrequency ablation of liver metastasis: potential impact on immune checkpoint inhibitor therapy","volume":"29","author":"Minami","year":"2019","journal-title":"Eur Radiol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.963031\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T06:47:53Z","timestamp":1660718873000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.963031\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,17]]},"references-count":40,"alternative-id":["10.3389\/fimmu.2022.963031"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.963031","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,17]]},"article-number":"963031"}}